According to a recent paper, even the responsiveness to targeted treatments is different in RA patients when associated with Sjögren’s syndrome, as follows: anti-tumor-necrosis factor (TNF)-alpha agents are less effective, whereas rituximab is more effective than in RA alone [28]. Here, TNF is linked to rheumatoid arthritis.